Renoprotective effect of tolvaptan in patients with new-onset acute heart failure.
Hiromi KinKoichiro MatsumuraYoshihiro YamamotoKenichi FujiiMunemitsu OtagakiHiroki TakahashiHaengnam ParkKei YoshiokaMitsuru YokoiTetsuro SugiuraIchiro ShiojimaPublished in: ESC heart failure (2020)
A lower incidence of WRF was observed in patients with new-onset AHF who were treated with the tolvaptan add-on therapy, specifically those with left ventricular systolic dysfunction and renal impairment on admission.
Keyphrases
- acute heart failure
- heart failure
- left ventricular
- cardiac resynchronization therapy
- hypertrophic cardiomyopathy
- emergency department
- acute myocardial infarction
- risk factors
- blood pressure
- mitral valve
- left atrial
- oxidative stress
- aortic stenosis
- diabetic nephropathy
- stem cells
- mesenchymal stem cells
- coronary artery disease